sk&f 81297 has been researched along with benzofurans in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gerlach, J; Lublin, H; Mørkeberg, F | 1 |
| Hiranita, T; Nawata, Y; Yamamoto, T | 1 |
2 other study(ies) available for sk&f 81297 and benzofurans
| Article | Year |
|---|---|
Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
Topics: Animals; Basal Ganglia Diseases; Behavior, Animal; Benzazepines; Benzofurans; Cebus; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Ergolines; Grooming; Hypnotics and Sedatives; Male; Motor Activity; Quinpirole; Raclopride; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides | 1994 |
A tryptamine-derived catecholaminergic enhancer, (-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP], attenuates reinstatement of methamphetamine-seeking behavior in rats.
Topics: Adrenergic Agents; Amisulpride; Amphetamine-Related Disorders; Animals; Benzazepines; Benzofurans; Central Nervous System Stimulants; Conditioning, Classical; Cues; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Extinction, Psychological; Male; Methamphetamine; Rats; Rats, Wistar; Self Administration; Sulpiride | 2010 |